Study of experimental drug combo for advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced prostate, pancreatic, or HPV-negative head and neck cancer that has spread and no longer responds to standard treatments.
- You should be well enough to carry out daily activities (ECOG score 0-2) and expected to live at least 3 more months.
- Your cancer must be measurable on scans (for prostate cancer, rising PSA levels or new lesions on bone scan also work).
- You need adequate blood cell counts, kidney function, and liver function as shown by recent blood tests.
- You must be willing to have a tumor biopsy before starting treatment and another one during the study (unless you have prostate cancer with only bone disease).
- You cannot have active autoimmune disease, serious heart rhythm problems, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial is testing two immunotherapy drugs (balstilimab and botensilimab) to see if they can shrink tumors in people with advanced pancreatic cancer that has worsened after at least one prior treatment. If you have microsatellite stable (MSS) disease, you may be eligible.
This trial tests a new combination of two treatments for prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if combining an immune-boosting drug with a vaccine can help the body fight the cancer more effectively.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.